TScan Therapeutics, Inc. TCRX
0.19 USD 0.00 (+0.22%)
At closeNov 12, 2026, 7:47 AM EST
0.19 0.00 0.00%
Pre-market · Nov 12, 7:47 AM ET
0.1778 Day range 0.1899
0.171 52-week range 1.47
- YTD
- -81.44%
- 1 year
- -84.79%
News
benzinga.com TScan Therapeutics Q3 EPS $(0.25) Misses $(0.19) Estimate, Sales $586.000K Beat $459.000K Estimate TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.19) by 31.58 percent. This is a 10.71 percent increase over losses…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 19.3% to $1.14 during Tuesday's after-market session. The company's market cap stands at $1.8 million. Edesa Biotech (NASDAQ:EDSA)…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX)…
benzinga.com HC Wainwright & Co. Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1 HC Wainwright & Co. analyst Andres Y. Maldonado downgrades TScan Therapeutics (NASDAQ:TCRX) from Buy to Neutral and lowers the price target from $7 to $1.
benzinga.com Wedbush Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1 Wedbush analyst David Nierengarten downgrades TScan Therapeutics (NASDAQ:TCRX) from Outperform to Neutral and lowers the price target from $5 to $1.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 54.3% to $10.17 during Wednesday's regular session. The company's market cap stands at $3.9 million. Gelteq (NASDAQ:GELS) shares…
benzinga.com Crude Oil Moves Higher; US Factory Orders Rise In July U.S. stocks rose mid-session, led by materials; factory orders beat estimates. Linkhome, Purple Biotech and GitLab surged, while Tscan and Credo fell.
benzinga.com TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction The strategic pivot focuses TScan's efforts on developing in vivo-engineered TCR-T therapies.
benzinga.com Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings U.S. stocks edged higher, led by the Dow and materials. Ollie’s beat EPS estimates; biotech and AI shares surged, while Tscan plunged 26%.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers BioVie (NASDAQ:BIVI) stock increased by 15.7% to $1.55 during Wednesday's after-market session. The market value of their outstanding shares is at $7.2 million. The company's, Q4 earnings…- benzinga.com Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics; Termination Of Collaboration Agreement Effective November 10, 2026 On August 12, 2026, TScan Therapeutics, Inc. (the "Company") received notice from Amgen Inc. ("Amgen") of its election to terminate, in its entirety, the Research Collaboration and License Agreement,
- benzinga.com HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $7 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $7 price target.
benzinga.com TScan Therapeutics Q2 EPS $(0.23) Misses $(0.21) Estimate, Sales $1.051M Miss $1.667M Estimate TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 17.86 percent increase over losses of…
benzinga.com Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $5 Price Target Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $5 price target.
benzinga.com TScan Says Cancer Therapy Data Support Move to Phase 3 Trial TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients…- benzinga.com TScan Therapeutics Partners With Cellares To Evaluate Automated Clinical Manufacturing Of TSC-101, The Company's Lead TCR-T Therapy Candidate For Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T…
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com TScan Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate, Sales $982.000K Miss $2.500M Estimate TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.20) by 10 percent. This is a 15.38 percent increase over losses of…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Wedbush Maintains Outperform on TScan Therapeutics, Raises Price Target to $5 Wedbush analyst David Nierengarten maintains TScan Therapeutics (NASDAQ:TCRX) with a Outperform and raises the price target from $4 to $5.
benzinga.com Earnings Breakdown: TScan Therapeutics Q4 - benzinga.com TScan Therapeutics Q4 EPS $(0.18) Beats $(0.24) Estimate, Sales $2.567M Beat $2.048M Estimate TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 26.53 percent. This is a 37.93 percent increase over losses of…
- benzinga.com TScan Therapeutics Completes Enrollment Into Cohort C Of ALLOHA Study Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing processReceived FDA clearance of INDs for TSC-102-A01 and TSC-102-A03…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com TScan Therapeutics Announced Saturday, Updated Data from the ALLOHA Phase 1 Heme Trial; 3/3 Of TSC-101-treated Patients Who Reached Two-year Follow-up Remained Relapse-free Vs. 1/4 In Control Arm TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $7 HC Wainwright & Co. analyst Andres Y. Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $10 to $7.
- benzinga.com TScan Therapeutics Q3 EPS $(0.28) Beats $(0.30) Estimate, Sales $2.511M Beat $1.980M Estimate TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 5.41 percent. This is a 12 percent decrease over losses of…
benzinga.com This Kimberly-Clark Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday 
benzinga.com Needham Maintains Buy on TScan Therapeutics, Lowers Price Target to $6 Needham analyst Gil Blum maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $9 to $6.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com TScan Therapeutics To Present New Research On T Cell Therapies At ACR Convergence 2025 In Chicago TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients…
- benzinga.com TScan Therapeutics Q2 EPS $(0.28), Inline, Sales $3.076M Beat $1.405M Estimate TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported…
- benzinga.com What Analysts Are Saying About TScan Therapeutics Stock
- benzinga.com HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $10 HC Wainwright & Co. analyst Andres Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $15 to $10.
- benzinga.com TScan Therapeutics Q1 EPS $(0.26) Beats $(0.29) Estimate, Sales $2.17M Beat $1.10M Estimate TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 18.75 percent increase over losses of…
- benzinga.com Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
- benzinga.com Needham Reiterates Buy on TScan Therapeutics, Maintains $9 Price Target Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $9 price target.
- benzinga.com Barclays Maintains Overweight on TScan Therapeutics, Lowers Price Target to $3 Barclays analyst Peter Lawson maintains TScan Therapeutics (NASDAQ:TCRX) with a Overweight and lowers the price target from $14 to $3.
- benzinga.com Breaking Down TScan Therapeutics: 4 Analysts Share Their Views
- benzinga.com HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $15 Price Target HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $15 price target.
- benzinga.com Needham Maintains Buy on TScan Therapeutics, Lowers Price Target to $9 Needham analyst Gil Blum maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $11 to $9.
- benzinga.com TScan Therapeutics Q4 2024 GAAP EPS $(0.30) Misses $(0.27) Estimate, Sales $665.00K Miss $1.35M Estimate, Cash, Cash Equivalents, And Marketable Securities Of $290.1M To Fund Operations Into Q1 Of 2027 TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 42.86 percent decrease over losses…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why Is TScan Therapeutics Stock Gaining Today? TScan Therapeutics' stock rises after announcing a $30 million financing deal with Lynx1, extending its cash runway into 2027.- benzinga.com Market-Moving News for December 26th ZCAR: 193% | Zoomcar Reports 43% Booking Surge, Revamps Website Ahead of Holiday Rush ADD: 161% | Color Star Technology Says Shaikh Humaid Abdulla Rashed Ahmed Almualla, A Prominent Member Of The UAE…